HLA-C and neoplasm: As the majority of cancer mutations are exclusive to each patient, it is imperative to initially procure tumor tissues from the patients and sequence their genomes through NGS or nanotechnology, among other methods, to predict mutant peptides that bind to the patient MHC subunits, accurately identify tumor antigens, and subsequently implement a personalized design, thereby effectively reducing the mutation load and enhancing the recognition and response of the immune system to tumor antigens.